[在慢性乙型肝炎中临床治愈和安全戒药]
1Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing 400016, China.
概括
在中国,预防乙型肝炎病毒 (HBV) 感染现在主要集中在治疗现有病例上. 实现功能性治疗需要通过免疫复合降低HBsAg水平,特别是在88%的难以治疗的患者中.
科学领域:
- 肝病学和病毒学:专注于病毒性肝炎,特别是乙型肝炎病毒 (HBV).
- 免疫学:探索免疫复合作为治疗策略.
- 公共卫生:解决中国的传染病控制和预防挑战.
背景情况:
- 乙型肝炎病毒 (HBV) 感染仍然是一个重大的全球健康问题.
- 免疫预防已经减少了新的HBV感染,将重点转移到管理现有病例.
- 减少慢性HBV的负担需要有效的治疗策略,以临床或功能治愈.
研究的目的:
- 讨论在中国控制HBV感染的不断变化的挑战.
- 探索在慢性HBV患者中实现临床或功能治疗的策略.
- 为HBV预防,治疗特征和安全戒药提供新的视角.
主要方法:
- 分析目前中国的HBV感染情况.
- 对实现功能治愈的治疗标准的审查,包括HBsAg水平.
- 讨论免疫复合作为HBV清除的驱动因素.
主要成果:
- 慢性HBV感染分为易于治疗的 (12%) 和难以治疗的 (88%) 组.
- 达到100 IU/mL以下的HBsAg水平是临床治愈的关键一步.
- 有效的免疫复原对于降低HBsAg水平至关重要.
结论:
- 在控制HBV的主要挑战已经从预防转移到管理现有感染.
- 为了实现HBV的功能治疗,需要降低HBsAg水平并恢复免疫系统.
- 对免疫复原的进一步研究对于开发有效的HBV治疗方法和安全的药物戒断协议至关重要.
相关概念视频
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...